Zimmer Biomet Holdings, Inc. (ZBH) Up 4.9% — Time to Get Exposure Before It Gaps?
Zimmer Biomet Holdings, Inc. (ZBH) advanced sharply in the latest session, with the stock climbing 4.90% to close at $94.13. That move represents a gain of $4.40 from the prior close at $89.73, signaling strong bullish activity and renewed upward momentum. The rally comes with trading volume of 1,293,492 shares on the NYSE, which is below the 90-day average of 2,038,057 shares, suggesting today’s strong price action developed without an unusually heavy influx of trading. Even so, the magnitude of the percentage move stands out as the stock continues to gain ground after recent consolidation.
From a longer-term perspective, ZBH is still trading below its 52-week high of $114.44 set on Apr. 3, 2025, leaving meaningful upside potential of roughly $20 per share before retesting that prior peak. This positions the current price action as a recovery phase rather than an extended breakout, with the stock working to regain territory within its one-year range. Within the medical and health care equipment space, Abbott Laboratories (ABT), Stryker (SYK), and Boston Scientific (BSX) have also seen periods of strength, but Zimmer Biomet’s nearly 5% single-session gain stands out as particularly robust. Overall, the latest move reflects a market that is increasingly willing to bid the shares higher, reinforcing a constructive near-term technical backdrop as the stock pushes further off recent lows and attempts to re-engage with its prior highs.
Why Zimmer Biomet Holdings, Inc. Price is Moving Higher
Zimmer Biomet Holdings, Inc. is seeing bullish sentiment build as investors react to a solid Q4 and full-year 2025 performance combined with a sizable new capital return plan. The company topped expectations with Q4 EPS of $2.42 versus $2.38 forecast and revenue of $2.244 billion versus $2.22 billion expected, capping a year in which sales rose 7.2% to $8.23 billion. Strength in the S.E.T. segment, which grew 18.7%, together with mid‑single‑digit growth in core knee and hip franchises, signals that Zimmer Biomet’s portfolio is gaining traction despite tariff headwinds and ongoing integration of three recent acquisitions. This operational momentum, alongside a 10.05% profit margin and revenue growth near 10%, is a key catalyst behind investor enthusiasm.
The announcement of a new $1.5 billion stock buyback authorization, on top of $250 million already repurchased in Q4 2025, is another clear driver of positive price momentum. An open‑ended repurchase program of this size typically underscores management’s confidence in the company’s cash generation and long‑term earnings power and can provide a supportive bid for the shares over time. While FY 2026 revenue guidance of 2.5%–4.5% and EPS of $8.30–$8.45 came in slightly below consensus and initially weighed on pre‑market trading, many investors appear to view the guidance as conservative given ongoing product launches such as ROSA Knee with OptimiZe and steady demand across the health care equipment and services space. Zimmer Biomet’s improving fundamentals and shareholder‑friendly capital allocation are reinforcing the case for continued upside.
What is the Zimmer Biomet Holdings, Inc. Rating - Should I Buy?
Weiss Ratings assigns ZBH a C rating. Current recommendation is Hold. This places Zimmer Biomet Holdings, Inc. in the middle of the Weiss scale — neither a standout Buy nor a high-risk Sell — but with several notable strengths that may appeal to investors seeking exposure to established medical technology names. Within its Health Care peer group, ZBH’s overall standing is comparable to Stryker Corporation (SYK, C) and broadly in line with Abbott Laboratories (ABT, C+) and Boston Scientific Corporation (BSX, C+).
The positive side of the story comes through clearly in the operational and balance sheet sub-indices. The Good Growth Index is supported by revenue growth of 9.71% and a profit margin of 10.05%, indicating a business that is expanding while maintaining profitability. The Good Efficiency Index, together with a return on equity of 6.42%, points to management generating respectable returns on shareholder capital. Most importantly, the Excellent Solvency Index signals a very strong financial foundation, which can be a key advantage in a sector requiring ongoing investment and innovation.
What holds ZBH back from a higher overall rating is weaker performance in stock-price-driven measures. The Weak Total Return Index and Weak Volatility Index indicate that, on a risk-adjusted basis, shareholders have not been rewarded as consistently as they might with higher-rated alternatives. A forward P/E of 22.25 also implies investors are paying a moderate premium for these fundamentals, which increases the bar for future execution.
Taken together, the C (Hold) rating means Zimmer Biomet currently offers a balanced risk/reward profile: solid underlying business quality and excellent solvency, tempered by less compelling total return and volatility characteristics compared with stronger-rated peers.
About Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc. is a leading global medical technology company focused on restoring mobility, alleviating pain and improving the quality of life for patients. Operating within the health care equipment and services industry, the company designs, manufactures and markets a broad portfolio of orthopedic reconstructive products, including knee, hip and shoulder implants used in joint replacement procedures. Zimmer Biomet also provides trauma products, sports medicine solutions and extremities implants that support surgeons in treating a wide range of musculoskeletal conditions. Its products are used extensively in hospitals, ambulatory surgery centers and specialty care facilities worldwide.
Beyond joint reconstruction and trauma, Zimmer Biomet has expanded into complementary categories that support the full episode of care in musculoskeletal health. This includes biologics, bone graft substitutes, surgical robotics, navigation systems and digital health technologies that assist clinicians with planning, execution and post-operative monitoring. The company’s spine and craniomaxillofacial offerings further extend its presence across the orthopedic and neurosurgical landscape. A key competitive advantage for Zimmer Biomet is its long-standing relationships with orthopedic surgeons, built around clinical education, product innovation and procedural support. By combining a broad product ecosystem with advanced enabling technologies, Zimmer Biomet is positioned as a comprehensive solutions provider within the global orthopedic and musculoskeletal care market.
Investor Outlook
With a C (Hold) Weiss Rating, Zimmer Biomet Holdings, Inc. (ZBH) offers potential for continued gains if it can build on operational execution and benefit from favorable health care demand trends. Investors may want to watch how the stock behaves around recent trading ranges, as well as any shifts in the overall sector that could eventually support an upgrade in its Hold rating. See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.
--